Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors.

Tormo E, Ballester S, Adam-Artigues A, Burgués O, Alonso E, Bermejo B, Menéndez S, Zazo S, Madoz-Gúrpide J, Rovira A, Albanell J, Rojo F, Lluch A, Eroles P.

Sci Rep. 2019 Mar 29;9(1):5316. doi: 10.1038/s41598-019-41472-y.

2.

Deregulation of SET is Associated with Tumor Progression and Predicts Adverse Outcome in Patients with Early-Stage Colorectal Cancer.

Cristóbal I, Torrejón B, Rubio J, Santos A, Pedregal M, Caramés C, Zazo S, Luque M, Sanz-Alvarez M, Madoz-Gúrpide J, Rojo F, García-Foncillas J.

J Clin Med. 2019 Mar 12;8(3). pii: E346. doi: 10.3390/jcm8030346.

3.

Analysis of Potential Alterations Affecting SETBP1 as a Novel Contributing Mechanism to Inhibit PP2A in Colorectal Cancer Patients.

Torrejón B, Cristóbal I, Caramés C, Prieto-Potín I, Chamizo C, Santos A, Sanz-Alvarez M, Serna-Blasco R, Luque M, Madoz-Gúrpide J, Rojo F, García-Foncillas J.

World J Surg. 2018 Nov;42(11):3771-3778. doi: 10.1007/s00268-018-4684-9.

PMID:
29796729
4.

PP2A regulates signaling through hormonal receptors in breast cancer with important therapeutic implications.

Cristóbal I, Torrejón B, Martínez-Useros J, Madoz-Gurpide J, Rojo F, García-Foncillas J.

Biochim Biophys Acta Rev Cancer. 2017 Dec;1868(2):435-438. doi: 10.1016/j.bbcan.2017.08.005. Epub 2017 Sep 12. Review.

PMID:
28916342
5.

Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer.

Sabbaghi M, Gil-Gómez G, Guardia C, Servitja S, Arpí O, García-Alonso S, Menendez S, Arumi-Uria M, Serrano L, Salido M, Muntasell A, Martínez-García M, Zazo S, Chamizo C, González-Alonso P, Madoz-Gúrpide J, Eroles P, Arribas J, Tusquets I, Lluch A, Pandiella A, Rojo F, Rovira A, Albanell J.

Clin Cancer Res. 2017 Nov 15;23(22):7006-7019. doi: 10.1158/1078-0432.CCR-17-0696. Epub 2017 Aug 18.

6.

Letter to the Editor: Is miR-199b-3p really involved in the migration ability of bone marrow mesenchymal stem cells?

Torrejón B, Cristóbal I, Madoz-Gúrpide J, Rojo F, García-Foncillas J.

J Leukoc Biol. 2017 May;101(5):1067. doi: 10.1189/jlb.2LT0117-034. No abstract available.

PMID:
28468982
7.

CIP2A confirms its prognostic value in triple-negative breast cancer.

Cristóbal I, Zazo S, Torrejón B, Pedregal M, Madoz-Gúrpide J, Lluch A, Eroles P, Rovira A, Albanell J, García-Foncillas J, Rojo F.

Oncogene. 2017 Jun 8;36(23):3357-3358. doi: 10.1038/onc.2016.474. Epub 2017 Jan 9. No abstract available.

PMID:
28068327
8.

Comment on 'MicroRNA-214 suppresses growth, migration and invasion through a novel target, high mobility group AT-hook 1, in human cervical and colorectal cancer cells'.

Cristóbal I, Torrejón B, Madoz-Gúrpide J, Rojo F, García-Foncillas J.

Br J Cancer. 2017 Jan;116(3):e7. doi: 10.1038/bjc.2016.409. Epub 2016 Dec 20. No abstract available.

9.

Recent Insights into the Development of Preclinical Trastuzumab- Resistant HER2+ Breast Cancer Models.

Gonzalez-Alonso P, Cristobal I, Zazo S, Martin-Aparicio E, Chamizo C, Madoz-Gurpide J, Rovira A, Eroles P, Lluch A, Albanell J, Rojo F.

Curr Med Chem. 2018;25(17):1976-1998. doi: 10.2174/0929867323666161216144659. Review.

PMID:
27993109
10.

Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines.

Zazo S, González-Alonso P, Martín-Aparicio E, Chamizo C, Cristóbal I, Arpí O, Rovira A, Albanell J, Eroles P, Lluch A, Madoz-Gúrpide J, Rojo F.

Am J Cancer Res. 2016 Nov 1;6(11):2661-2678. eCollection 2016.

11.

PP2A plays a key role in inflammation and cancer through tristetraprolin activation.

Cristóbal I, Torrejón B, Madoz-Gúrpide J, Rojo F, García-Foncillas J.

Ann Rheum Dis. 2017 May;76(5):e11. doi: 10.1136/annrheumdis-2016-210684. Epub 2016 Nov 3. No abstract available.

PMID:
27811146
12.

c-Jun N-Terminal Kinase Inactivation by Mitogen-Activated Protein Kinase Phosphatase 1 Determines Resistance to Taxanes and Anthracyclines in Breast Cancer.

Rincón R, Zazo S, Chamizo C, Manso R, González-Alonso P, Martín-Aparicio E, Cristóbal I, Cañadas C, Perona R, Lluch A, Eroles P, García-Foncillas J, Albanell J, Rovira A, Madoz-Gúrpide J, Rojo F.

Mol Cancer Ther. 2016 Nov;15(11):2780-2790. Epub 2016 Sep 6.

13.

Potential therapeutic value of miR-425-5p in metastatic colorectal cancer.

Cristóbal I, Madoz-Gúrpide J, Rojo F, García-Foncillas J.

J Cell Mol Med. 2016 Nov;20(11):2213-2214. doi: 10.1111/jcmm.12902. Epub 2016 Jul 9. No abstract available.

14.

Downregulation of microRNA-199b predicts unfavorable prognosis and emerges as a novel therapeutic target which contributes to PP2A inhibition in metastatic colorectal cancer.

Cristóbal I, Caramés C, Rincón R, Manso R, Madoz-Gúrpide J, Torrejón B, González-Alonso P, Rojo F, García-Foncillas J.

Oncotarget. 2017 Jun 20;8(25):40169-40180. doi: 10.18632/oncotarget.11174.

15.
16.

Cross Talk between Wnt/β-Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic Implications.

Cristóbal I, Rojo F, Madoz-Gúrpide J, García-Foncillas J.

Mol Cell Biol. 2016 May 31;36(12):1734-9. doi: 10.1128/MCB.00130-16. Print 2016 Jun 15. Review.

17.

Deregulation of miR-92a in locally advanced rectal cancer.

Cristóbal I, Torrejón B, Madoz-Gúrpide J, Rojo F, García-Foncillas J.

Genes Chromosomes Cancer. 2016 Jul;55(7):612. doi: 10.1002/gcc.22357. Epub 2016 May 2. No abstract available.

PMID:
27015298
18.

Potential anti-tumor effects of FTY720 associated with PP2A activation: a brief review.

Cristóbal I, Madoz-Gúrpide J, Manso R, González-Alonso P, Rojo F, García-Foncillas J.

Curr Med Res Opin. 2016 Jun;32(6):1137-41. doi: 10.1185/03007995.2016.1162774. Epub 2016 Mar 16. Review.

PMID:
26950691
19.

Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer.

Chamizo C, Zazo S, Dómine M, Cristóbal I, García-Foncillas J, Rojo F, Madoz-Gúrpide J.

BMC Pulm Med. 2015 Oct 26;15:132. doi: 10.1186/s12890-015-0132-x.

20.

Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer.

Madoz-Gúrpide J, Zazo S, Chamizo C, Casado V, Caramés C, Gavín E, Cristóbal I, García-Foncillas J, Rojo F.

J Transl Med. 2015 Aug 29;13:282. doi: 10.1186/s12967-015-0633-7.

21.

Clinical Value of miR-26b Discriminating Ulcerative Colitis-associated Colorectal Cancer in the Subgroup of Patients with Metastatic Disease.

Cristóbal I, Manso R, Gónzález-Alonso P, Madoz-Gúrpide J, Rojo F, García-Foncillas J.

Inflamm Bowel Dis. 2015 Oct;21(10):E24-5. doi: 10.1097/MIB.0000000000000572. No abstract available.

PMID:
26308439
22.

Pyrosequencing-Based Assays for Rapid Detection of HER2 and HER3 Mutations in Clinical Samples Uncover an E332E Mutation Affecting HER3 in Retroperitoneal Leiomyosarcoma.

González-Alonso P, Chamizo C, Moreno V, Madoz-Gúrpide J, Carvajal N, Daoud L, Zazo S, Martín-Aparicio E, Cristóbal I, Rincón R, García-Foncillas J, Rojo F.

Int J Mol Sci. 2015 Aug 17;16(8):19447-57. doi: 10.3390/ijms160819447.

23.

PP2A inhibition as a novel therapeutic target in castration-resistant prostate cancer.

González-Alonso P, Cristóbal I, Manso R, Madoz-Gúrpide J, García-Foncillas J, Rojo F.

Tumour Biol. 2015 Aug;36(8):5753-5. doi: 10.1007/s13277-015-3849-5. Epub 2015 Aug 4.

PMID:
26234767
24.

Clinical Usefulness of 5-FU Metabolic Enzymes as Predictive Markers of Response to Chemotherapy in Colorectal Cancer.

Cristóbal I, Manso R, González-Alonso P, Madoz-Gurpide J, Rojo F, García-Foncillas J.

World J Surg. 2016 Apr;40(4):1017-8. doi: 10.1007/s00268-015-3176-4. No abstract available.

PMID:
26228063
25.

MiR-29c downregulation contributes to metastatic progression in colorectal cancer.

Cristóbal I, Madoz-Gúrpide J, Manso R, Rojo F, García-Foncillas J.

Ann Oncol. 2015 Oct;26(10):2199-200. doi: 10.1093/annonc/mdv302. Epub 2015 Jul 17. No abstract available.

26.

Activation of the Tumor Suppressor PP2A Emerges as a Potential Therapeutic Strategy for Treating Prostate Cancer.

Cristóbal I, González-Alonso P, Daoud L, Solano E, Torrejón B, Manso R, Madoz-Gúrpide J, Rojo F, García-Foncillas J.

Mar Drugs. 2015 May 27;13(6):3276-86. doi: 10.3390/md13063276.

27.

Determination of True ERBB2 Gene Amplification in Breast Cancer by Quantitative PCR Using a Reference and a Novel Control Gene.

Chamizo C, Rojo F, Madoz-Gúrpide J.

Appl Immunohistochem Mol Morphol. 2016 Mar;24(3):179-87. doi: 10.1097/PAI.0000000000000160.

PMID:
25789534
28.

PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects.

Rincón R, Cristóbal I, Zazo S, Arpí O, Menéndez S, Manso R, Lluch A, Eroles P, Rovira A, Albanell J, García-Foncillas J, Madoz-Gúrpide J, Rojo F.

Oncotarget. 2015 Feb 28;6(6):4299-314.

29.

Deregulation of the PP2A inhibitor SET shows promising therapeutic implications and determines poor clinical outcome in patients with metastatic colorectal cancer.

Cristóbal I, Rincón R, Manso R, Caramés C, Zazo S, Madoz-Gúrpide J, Rojo F, García-Foncillas J.

Clin Cancer Res. 2015 Jan 15;21(2):347-56. doi: 10.1158/1078-0432.CCR-14-0724. Epub 2014 Nov 11.

30.

Comment on 'TAp63 suppress metastasis via miR-133b in colon cancer cells'.

Cristobal I, Madoz-Gurpide J, Martin-Aparicio E, Carames C, Aguilera O, Rojo F, Garcia-Foncillas J.

Br J Cancer. 2014 Dec 9;111(12):2369. doi: 10.1038/bjc.2014.390. Epub 2014 Jul 24. No abstract available.

31.

Phosphorylated protein phosphatase 2A determines poor outcome in patients with metastatic colorectal cancer.

Cristóbal I, Manso R, Rincón R, Caramés C, Zazo S, Del Pulgar TG, Cebrián A, Madoz-Gúrpide J, Rojo F, García-Foncillas J.

Br J Cancer. 2014 Aug 12;111(4):756-62. doi: 10.1038/bjc.2014.376. Epub 2014 Jul 8.

32.

Hyperphosphorylation of PP2A in colorectal cancer and the potential therapeutic value showed by its forskolin-induced dephosphorylation and activation.

Cristóbal I, Rincón R, Manso R, Madoz-Gúrpide J, Caramés C, del Puerto-Nevado L, Rojo F, García-Foncillas J.

Biochim Biophys Acta. 2014 Sep;1842(9):1823-9. doi: 10.1016/j.bbadis.2014.06.032. Epub 2014 Jul 2.

33.

Deregulation of miR-200b, miR-200c and miR-429 indicates its potential relevant role in patients with colorectal cancer liver metastasis.

Cristóbal I, Rincón R, Manso R, Caramés C, Aguilera O, Madoz-Gurpide J, Rojo F, García-Foncillas J.

J Surg Oncol. 2014 Sep;110(4):484-5. doi: 10.1002/jso.23661. Epub 2014 Jun 10. No abstract available.

PMID:
24916918
34.

Clinical significance of miR-126 in colorectal cancer.

Cristóbal I, Aguilera O, García-Foncillas J, Zazo S, Madoz-Gúrpide J, Rojo F.

Genes Chromosomes Cancer. 2014 Oct;53(10):881. doi: 10.1002/gcc.22192. Epub 2014 Jun 4. No abstract available.

PMID:
24898922
35.

Potential involvement of protein phosphatase 2A in temsirolimus-mediated resensitization to cetuximab in colon cancer cells.

Cristóbal I, Manso R, Rincón R, Madoz-Gúrpide J, Caramés C, Rojo F, García-Foncillas J.

J Cancer Res Clin Oncol. 2014 Jul;140(7):1249-50. doi: 10.1007/s00432-014-1707-2. Epub 2014 May 15. No abstract available.

PMID:
24828260
36.

Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy.

del Puerto-Nevado L, Rojo F, Zazo S, Caramés C, Rubio G, Vega R, Chamizo C, Casado V, Martínez-Useros J, Rincón R, Rodríguez-Remírez M, Borrero-Palacios A, Cristóbal I, Madoz-Gúrpide J, Aguilera O, García-Foncillas J.

Br J Cancer. 2014 May 27;110(11):2700-7. doi: 10.1038/bjc.2014.225. Epub 2014 May 1.

37.

Downregulation of miR-214 is specific of liver metastasis in colorectal cancer and could play a role determining the metastatic niche.

Cristóbal I, Caramés C, Madoz-Gúrpide J, Rojo F, Aguilera O, García-Foncillas J.

Int J Colorectal Dis. 2014 Jul;29(7):885. doi: 10.1007/s00384-014-1872-4. Epub 2014 Apr 24. No abstract available.

PMID:
24760176
38.

Up-regulation of c-Cbl suggests its potential role as oncogene in primary colorectal cancer.

Cristóbal I, Manso R, Rincón R, Caramés C, Madoz-Gúrpide J, Rojo F, García-Foncillas J.

Int J Colorectal Dis. 2014 May;29(5):641. doi: 10.1007/s00384-014-1839-5. Epub 2014 Feb 15. No abstract available.

PMID:
24525700
39.

PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential.

Cristóbal I, Manso R, Rincón R, Caramés C, Senin C, Borrero A, Martínez-Useros J, Rodriguez M, Zazo S, Aguilera O, Madoz-Gúrpide J, Rojo F, García-Foncillas J.

Mol Cancer Ther. 2014 Apr;13(4):938-47. doi: 10.1158/1535-7163.MCT-13-0150. Epub 2014 Jan 21.

40.

Mining sarcomas by proteomics approaches: Ewing sarcoma on the spotlight.

Mackintosh C, Madoz-Gúrpide J.

Recent Pat Biotechnol. 2013 Aug;7(2):98-111. Review.

PMID:
23848272
41.

The molecular pathogenesis of Ewing's sarcoma.

Mackintosh C, Madoz-Gúrpide J, Ordóñez JL, Osuna D, Herrero-Martín D.

Cancer Biol Ther. 2010 May 1;9(9):655-67. Epub 2010 May 12. Review.

PMID:
20215864
42.

Advances in Ewing's sarcoma research: where are we now and what lies ahead?

Ordóñez JL, Osuna D, Herrero D, de Alava E, Madoz-Gúrpide J.

Cancer Res. 2009 Sep 15;69(18):7140-50. doi: 10.1158/0008-5472.CAN-08-4041. Epub 2009 Sep 8. Review.

43.

Other targetable sarcomas.

Pires de Camargo V, van de Rijn M, Maestro R, de Alava E, Madoz-Gúrpide J, Pilotti S, von Mehren M, Pedeutour F, Maki RG, Rutkowski P, Thomas DM.

Semin Oncol. 2009 Aug;36(4):358-71. doi: 10.1053/j.seminoncol.2009.06.008. Review. Erratum in: Semin Oncol. 2009 Oct;36(5):489. Maestro, Roberta [added].

PMID:
19664496
44.

Targeting sarcomas by proteomic approaches.

Madoz-Gúrpide J.

Proteomics Clin Appl. 2009 Jul;3(7):758-73. doi: 10.1002/prca.200800229. Epub 2009 Jun 25.

PMID:
21136985
45.

Stable interference of EWS-FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target.

Herrero-Martín D, Osuna D, Ordóñez JL, Sevillano V, Martins AS, Mackintosh C, Campos M, Madoz-Gúrpide J, Otero-Motta AP, Caballero G, Amaral AT, Wai DH, Braun Y, Eisenacher M, Schaefer KL, Poremba C, de Alava E.

Br J Cancer. 2009 Jul 7;101(1):80-90. doi: 10.1038/sj.bjc.6605104. Epub 2009 Jun 2.

46.

Targeting sarcomas: therapeutic targets and their rational.

Ordóñez JL, Martins AS, Osuna D, Madoz-Gúrpide J, de Alava E.

Semin Diagn Pathol. 2008 Nov;25(4):304-16. Review.

PMID:
19013896
47.

A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study.

Martins AS, Ordoñez JL, García-Sánchez A, Herrero D, Sevillano V, Osuna D, Mackintosh C, Caballero G, Otero AP, Poremba C, Madoz-Gúrpide J, de Alava E.

Cancer Res. 2008 Aug 1;68(15):6260-70. doi: 10.1158/0008-5472.CAN-07-3074.

48.

Integral protein microarrays for the identification of lung cancer antigens in sera that induce a humoral immune response.

Madoz-Gúrpide J, Kuick R, Wang H, Misek DE, Hanash SM.

Mol Cell Proteomics. 2008 Feb;7(2):268-81. Epub 2007 Oct 4.

49.

A proteomics analysis of cell signaling alterations in colorectal cancer.

Madoz-Gúrpide J, Cañamero M, Sanchez L, Solano J, Alfonso P, Casal JI.

Mol Cell Proteomics. 2007 Dec;6(12):2150-64. Epub 2007 Sep 11.

50.

Proteomics-based validation of genomic data: applications in colorectal cancer diagnosis.

Madoz-Gúrpide J, López-Serra P, Martínez-Torrecuadrada JL, Sánchez L, Lombardía L, Casal JI.

Mol Cell Proteomics. 2006 Aug;5(8):1471-83. Epub 2006 May 29.

Supplemental Content

Loading ...
Support Center